RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Making Sense of FDA’s Postmarket Surveillance Program

Making Sense of FDA’s Postmarket Surveillance Program

Posted 01 September 2009 | By

Throughout the clinical development process, sponsors maintain a laser-like focus on getting to the finish line-receiving marketing approval from the US Food and Drug Administration (FDA) for a drug, biologic or medical device. But what happens next, when the product is launched and is now available to the public? That is when sponsors realize that the game really is only half over, and postmarket surveillance comes into play to monitor the newly approved product throughout its lifecycle.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.